Navigation Links
Replidyne Announces Restructuring of Operations
Date:8/27/2008

LOUISVILLE, Colo., Aug. 27 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) today announced the restructuring of its operations reducing its current employee headcount by approximately 80% to 5 employees in actions that are scheduled to take place during September 2008 and October 2008. As a result of these actions Replidyne will suspend further development activities of REP3123, its investigational agent for the treatment of Clostridium difficile (C. difficile) bacteria and C. difficile Infection (CDI), and novel anti-infective compounds based on its DNA replication inhibition technology. Following completion of the restructuring actions, the Company will limit its activities to completing its review of previously announced strategic alternatives.

"The actions outlined today position us to focus on the strategic alternatives process that we initiated several months ago, as well as preserve our cash resources," stated Kenneth J. Collins, President and Chief Executive Officer of Replidyne. "The process we are conducting involves a number of alternatives including merger or acquisition of the company together with the possible sale of our C. difficile and DNA replication inhibition programs. While the process is ongoing, we are encouraged by our progress to date."

The Company estimates that it will incur $3.1 million of costs related to the restructuring of its operations comprised of $1.6 million for employee severance benefits, $0.8 million for lease payments in excess of expected sub-lease income and $0.7 million of non-cash expense for the write down of impaired fixed assets.

At July 31, 2008 the Company reported $60.7 million in cash and cash equivalents and short term investments and had recorded current l
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
2. ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association
3. DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology
4. Genmab Announces 2008 First Half Year Results
5. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
6. USP announces new tool to help prevent medication mix-ups due to look alike/sound alike drug names
7. Hartwell Medical Announces Release of CombiCarrierII Scoop Backboard to EMS Market
8. iCan Benefit Group, LLC Announces: Major Medical Division Now Offers Avalon Healthcare Products
9. NxStage Announces Presentation of Data at the American Society of Nephrologys Renal Week 2008 Annual Meeting
10. Allscripts Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders
11. Corbett Accel Healthcare Group Announces Promotion of Geoff Melick to Executive Vice President, Interactive Marketing & eInnovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... December 26, 2014 Pentec Health, Inc. ... the state of Pennsylvania for 2014. The awards program, ... programs of its kind in the country. The program ... Pennsylvania Department of Community and Economic Development, the Pennsylvania ... and the Central Penn Business Journal. , ...
(Date:12/25/2014)... The click strand woven bamboo ... durability. Today, the business announces a click strand ... Jan. 30, 2015. , Click strand woven bamboo ... is a well-known brand in the bamboo industry. ... a reliable bamboo flooring supplier. , “We are ...
(Date:12/25/2014)... 2014 Recently, iFitDress.com, the popular online supplier ... announced its new selection of black one-shoulder cocktail dresses ... now; they are available at discounted prices, up to 70% ... will last for three weeks only. You know, we have ... are interested in our new items can visit our website ...
(Date:12/25/2014)... Hills, California (PRWEB) December 25, 2014 ... her home in Woodland Hills, California after an 8 ... passed away on Christmas Eve evening in her home ... with aggressive metastatic breast cancer. , ... for over forty years, she pioneered and championed many ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... , , , , ... of the 32 filed cases around the country have filed a joint ... to Chief Judge James G. Carr of the United States District Court ... July 24, 2009, before the Judicial Panel on Multidistrict Litigation in Washington, ...
... MONICA, Calif., July 24 The following advisory was issued by Consumer Watchdog: , , ... health insurance , , When : , ... , Hilton , Civil Justice Foundation Breakfast of Champions , ... San Francisco, CA 94102 , , What : , ...
... , , WASHINGTON, July 24 ... Department of Veterans Affairs (VA) medical centers, attained over one billion ... , , "Using this technology, ... database, allowing VA physicians immediate access to patient records regardless of ...
... The Hispanic got milk? Milk Mustache,Mobile Tour visited New York as ... to reintroduce Hispanics to this nutrient powerhouse and its,array of benefits. ... local residents not only to live well, but to drink well,with ... the events, Hispanic mothers were given the opportunity to enter the,Milk ...
... Medicine finds suggestive but limited evidence that exposure to Agent ... associated with an increased chance of developing ischemic heart disease ... the latest in a congressionally mandated series by the IOM ... effects of these herbicides and a type of dioxin -- ...
... , , OKLAHOMA CITY, July ... continues to see job opportunities for qualified professionals in the Oklahoma City, ... 6%, Adecco USA currently has demand for 100 pharmacy technicians in the ... , , Over the past year the ...
Cached Medicine News:Health News:Motion Filed to Consolidate Yasmin/YAZ Litigation in Toledo, Ohio 2Health News:CIGNA Whistleblower Calls for More Heath Insurance Accountability in Heath Care Reform 2Health News:VA Medical Imaging Reaches Record Level 2Health News:The Hispanic got milk? Campaign Visited New York July 18 - July 22 2Health News:Limited data suggest possible association between Agent Orange exposure 2Health News:Limited data suggest possible association between Agent Orange exposure 3Health News:Wanted: Oklahoma City Licensed Pharmacy Technicians 2
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... 2011 Reportlinker.com announces that ... is available in its catalogue: ... Drug Safety Strategies and Risk ... clinical success ...
... FRANCISCO, Calif., Oct. 26, 2011 Onyx Pharmaceuticals, ... results from a Bayer HealthCare Pharmaceuticals Phase 3 ... for the treatment of patients with metastatic colorectal ... standard therapies. The trial met its primary endpoint ...
Cached Medicine Technology:Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 2Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 3Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 4Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 5
For use with catalog #0540....
Enzyme Immunoassay of D-Dimer by ELISA Method, 96 tests....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Latex Agglutination Slide Test for the Qualitative and Semi-Quantitative Determination of D-Dimer in plasma, 60 tests....
Medicine Products: